Navigation Links
Amicus Therapeutics Announces Second Quarter 2009 Financial Results
Date:8/5/2009

.5 million as compared to $7.4 million in the same period in 2008.

Amicus recorded revenue during the second quarter of 2009 representing two different revenue streams from the Shire agreement. Upon signing the agreement, Amicus received an upfront payment of $50 million that will be recognized as revenue on a straight-line basis over 18 years from the date of the agreement. In the second quarter of 2009, Amicus recognized $0.7 million of the Shire upfront payment and $4.7 million of research revenue on reimbursed research and development costs.

The differences between U.S. GAAP and non U.S. GAAP financial results are itemized in Tables 2 and 3 and are primarily due to pre-tax stock compensation expense.

Use of Non-GAAP Financial Measures

Amicus' "non-GAAP net loss" and "non-GAAP diluted net loss per common share" financial measures are defined as reported, or GAAP, net loss and diluted net loss per common share excluding certain items further discussed below. Amicus' management uses these non-GAAP financial measures to establish financial goals and to gain an understanding of the comparative financial performance of Amicus from year to year and quarter to quarter. Accordingly, Amicus believes investors' understanding of Amicus' financial performance is enhanced as a result of disclosing these non-GAAP financial measures. Non-GAAP net loss and diluted net loss per common share should not be viewed in isolation or as a substitute for reported, or GAAP net loss and diluted net loss per common share.

(1) Stock option expense -- Non-GAAP net loss and diluted net loss per common share exclude the impact of the stock option expense recorded in accordance with SFAS No. 123R. Amicus believes that excluding the impact of expensing stock options better reflects the recurring economic characteristics of its business.

Conference Call and Webcast'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... June 30, 2015 , ... ... to provide advanced scientific research into new classes of Nanoscale Graphene-based materials poised ... Touted as 'the wonder material of the 21st Century' by the researchers who ...
(Date:6/30/2015)... 2015  Juniper Pharmaceuticals, Inc. (Nasdaq: JNP ), ... that address unmet medical needs in women,s health, ... will present at the Cantor Fitzgerald Inaugural Healthcare ... , 4:45 PM EDTLocation: , Le Parker Meridien ... www.juniperpharma.com, under  ,Investor, or  click here ...
(Date:6/30/2015)... ... June 30, 2015 , ... uBiome and ... insights on mechanics of fecal microbiota transplantation in C. difficile patients. , SAN ... of patients undergoing fecal microbiota transplantation (FMT) as a treatment for Clostridium difficile ...
(Date:6/30/2015)... Falls Church, VA (PRWEB) , ... June 30, ... ... technology, and strategy services to the federal government, announced in a paper published ... Noblis scientists uncovered a potential problem with the diagnostic techniques currently used to ...
Breaking Biology Technology:How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 3How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 4Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 3Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 2Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 3Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 4
... , , PHILADELPHIA, Sept. 14 ERT ... the Company,s President and CEO, and Keith Schneck, the Company,s Executive Vice ... Conference at 11:00 AM EDT on September 21, 2009 in New ... access the presentation by visiting the Company,s corporate website at ...
... BOTHELL, Wash., Sept. 14 BioLife Solutions, ... and marketer of biopreservation tools for cells, tissues, and ... proprietary HypoThermosol and CryoStor biopreservation media products under the ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090814/BIOLIFELOGO ) , , ...
... Mass., Sept. 14 Ironwood Pharmaceuticals, Inc. today announced that Thomas ... vice president of marketing and sales. Mr. McCourt will be responsible ... marketing and sales team. , , (Logo: ... Mr. McCourt comes to Ironwood from Amgen, where he led the ...
Cached Biology Technology:ERT to Present at UBS Global Life Sciences Conference on September 21, 2009 2BioLife Solutions Announces HypoThermosol(R) and CryoStor(TM) Distribution Agreement With Sigma-Aldrich 2BioLife Solutions Announces HypoThermosol(R) and CryoStor(TM) Distribution Agreement With Sigma-Aldrich 3Ironwood Appoints Thomas McCourt As Chief Commercial Officer and Senior Vice President of Marketing and Sales 2
(Date:6/24/2015)... The biologics safety testing market is growing ... market include growth of the pharmaceutical and biological industries ... the years, the number of drug approvals in North ... FDA approved 225 drug applications and Health Canada approved ... accounted for 3,822 of the pharmaceutical and ...
(Date:6/24/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/hhwlfj/huawei_ascend ... "Huawei Ascend Mate 7 Fingerprint Sensor - Reverse ... Huawei,s technological choice for the fingerprint sensor ... and Samsung,s one. The Ascend Mate 7 presents ... a main actor in capacitive sensing human interface ...
(Date:6/23/2015)... Research and Markets( ... "Body-Worn Temperature Sensors Market - Global Industry ... - 2020" report to their offering. ... global body-worn temperature sensors market. The global body-worn ... basis of types, care setting, patient demographic, applications ...
Breaking Biology News(10 mins):Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2Body-Worn Temperature Sensors Market - Global Industry Analysis 2
... state-of-the-art electron microscopy techniques, a team led by researchers ... described the precise arrangement of chemoreceptorsthe receptors that sense ... have found that this specific architecture is the same ... that this is a stable, universal structure that has ...
... EAST LANSING, Mich. - It,s been cultivated for at least ... every continent except Antarctica. Now the humble potato has had ... important vegetable worldwide," said Robin Buell, an MSU associate professor ... released the first draft sequence of the potato genome. "This ...
... chemicals to observe how basic cellular activities differ between healthy ... too slow or too toxic to perform on live cells. ... Faculty of 1000 Biology and leading authority in chemistry and ... chemical reaction to make live cancer cells light up quickly ...
Cached Biology News:Caltech scientists get detailed glimpse of chemoreceptor architecture in bacterial cells 2Caltech scientists get detailed glimpse of chemoreceptor architecture in bacterial cells 3Caltech scientists get detailed glimpse of chemoreceptor architecture in bacterial cells 4MSU scientist helps map potato genome, hope to improve crop yield 2
Human Cell Line Slides...
... Level 2 Detection System combines the ... bonding principle and Signets unique formulation ... specificity and reliablility. Signet reagents will ... manual and automated protocols. ,Signets USA ...
XPMC2H Immunogen: XPMC2H (NP_065118, 323 a.a. ~ 423 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Ideally suited for resolving DNA and RNA 10-1000 bases especially PCR products ranging from 100-1000 bp. Gelling temp. (4%) 27C Melting temperature 65C. EEO: 0.10 Rnase/Dnase: none detected...
Biology Products: